Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31069706 | 1.00 | TSHR (0.61) | TSHRNAAAHPGDHCAR2RAD52 | |
| SCHEMBL2158706 | 1.00 | TSHR (0.61) | TSHRNAAAHPGDHCAR2RAD52 | |
| SCHEMBL6449183 | 0.98 | TSHR (0.58) | TSHRNAAAHPGDHCAR2RAD52 | |
| SCHEMBL27377604 | 0.91 | TSHR (0.54) | TSHRNAAAHPGDHCAR2RAD52 | |
| SCHEMBL9788553 | 0.90 | TSHR (0.77) | TSHRNAAAHPGDHCAR2RAD52 | |
| SCHEMBL930891 | 0.90 | TSHR (0.77) | TSHRNAAAHPGDHCAR2RAD52 | |
| SCHEMBL15130313 | 0.88 | TSHR (0.74) | TSHRNAAAHPGDHCAR2RAD52 | |
| SCHEMBL6274691 | 0.86 | TSHR (0.53) | TSHRNAAAHPGDHCAR2RAD52 | |
| SCHEMBL10948447 | 0.85 | TSHR (0.61) | TSHRNAAAHPGDHCAR2RAD52 | |
| SCHEMBL9718041 | 0.84 | TSHR (0.48) | TSHRHPGDHCAR2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735004-B2 | Overcharge inhibitor, and nonaqueous electrolyte solution and secondary battery using the same | HITACHI, LTD. (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2710045-A1 | HALOGEN FREE THERMOSET RESIN SYSTEM FOR LOW DIELECTRIC LOSS AT HIGH FREQUENCY APPLICATIONS | Huntsman Advanced Materials Americas LLC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20140057086-A1 | Halogen Free Thermoset Resin System for Low Dielectric Loss at High Frequency Applications | HUNTSMAN ADVANCED MATERIALS AMERICAS LLC (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2012158415-A1 | HALOGEN FREE THERMOSET RESIN SYSTEM FOR LOW DIELECTRIC LOSS AT HIGH FREQUENCY APPLICATIONS | HUNTSMAN ADVANCED MATERIALS AMERICAS LLC (US) | 2012-11-22 | — | — | WO | disclosed |
| EP-2355228-A1 | Overcharge inhibitor, and nonaqueous electrolyte solution and secondary battery using the same | Hitachi Ltd. (JP) | 2011-08-10 | — | — | EP | disclosed |
| US-20110189550-A1 | OVERCHARGE INHIBITOR, AND NONAQUEOUS ELECTROLYTE SOLUTION AND SECONDARY BATTERY USING THE SAME | HITACHI, LTD. | 2011-08-04 | — | — | US | disclosed |
| US-7803298-B2 | Molding material, molded part, and method for manufacturing them | SUMITOMO ELECTRIC FINE POLYMER, INC. (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090085260-A1 | BIODEGRADABLE MATERIAL AND PROCESS FOR PRODUCING THE SAME | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20090030160-A1 | Polylactic Acid Complex and Production Method Thereof | SUMITOMO ELECTRIC FINE POLYMER INC. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20080213209-A1 | Process for Producing Cross-Linked Material of Polylactic Acid and Cross-Linked Material of Polylactic Acid | SUMITOMO ELECTRIC FINE POLYMER, INC. (JP) | 2008-09-04 | — | — | US | disclosed |
| US-20080036119-A1 | Molding material, molded part, and method for manufacturing them | SUMITOMO ELECTRIC FINE POLYMER, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20060160984-A1 | Biodegradable material and process for producing the same | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 2006-07-20 | — | — | US | disclosed |
| US-20050242466-A1 | Process for producing transparent material made of polylactic acid and transparent material made of polylactic acid | SUMITOMO ELECTRIC FINE POLYMER, INC. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-0910351-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0907666-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997049736-A2 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049387-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090085260-A1 | BIODEGRADABLE MATERIAL AND PROCESS FOR PRODUCING THE SAME | TST, PCMT1, XRCC6 | TSHR 4354/4885NAAA 276/4885HPGD 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.